Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat with Temozolomide and Radiation in Newly Diagnosed Glioblastoma
NCT00731731Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2009
- Primary completion
- Feb 2014
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in glioblastoma (GBM) and Gliosarcoma (GS), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose of Vorinostat at 10 weeks and Overall Survival at 15 months. Started Jul 2009; status: completed.
02
Drugs
vorinostat
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT00731731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00731731.